Immune checkpoint inhibitors(ICIs),including humanized anti-programmed cell death protein 1/programmed death-ligand 1(anti-PD-1/PD-L1)monoclonal antibodies(mAbs),such as pembrolizumab,have transformed cancer treatment...Immune checkpoint inhibitors(ICIs),including humanized anti-programmed cell death protein 1/programmed death-ligand 1(anti-PD-1/PD-L1)monoclonal antibodies(mAbs),such as pembrolizumab,have transformed cancer treatment.Pembrolizumab was initially approved as a three-weekly(Q3W)2 mg/kg weight-based dose by the Food and Drug Administration(FDA),which was later replaced by a 200 mg Q3W fixed-dose,mainly based on in silico simulations.展开更多
文摘Immune checkpoint inhibitors(ICIs),including humanized anti-programmed cell death protein 1/programmed death-ligand 1(anti-PD-1/PD-L1)monoclonal antibodies(mAbs),such as pembrolizumab,have transformed cancer treatment.Pembrolizumab was initially approved as a three-weekly(Q3W)2 mg/kg weight-based dose by the Food and Drug Administration(FDA),which was later replaced by a 200 mg Q3W fixed-dose,mainly based on in silico simulations.
